ime izdelka:Goserelin Acetate
Sopomenke: PYR-HIS-TRP-SER-TYR-D-SER(TBU)-LEU-ARG-PRO-AZAGLY-NH2;[(T-BU)DSER6, (AZA)GLY10]-LH-RH;[(T-BU)DSER6, (AZA)GLY10]-LUTEINIZING HORMONE-RELEASING HORMONE;GLP-HIS-TRP-SER-TYR-D-SER(TBU)-LEU-ARG-PRO-AZA-GLY-NH2;(D-SER(TBU)6,AZAGLY10)-LHRH;(D-Ser(tBu)6,Azagly10)-LHRH acetate salt;Goserelin HCl;GOSERELIN HCL[PYR-HIS-TRP-SER-TYR-D-SER(T-BU)-LEU-ARG-PRO-AZAGLY-NH2]
CAS: 145781-92-6
MF: C59H84N18O14
MW: 1269.41
Kategorije izdelkov: Amino Acid Derivatives;Peptide;Intermediati & Fine kemikalije;Peptidi;Farmacevtski izdelki;Pepetides
Datoteka Mol: 145781-92-6.mol
Goserelin acetate is an anti-cancer drug, classified as an analog of naturally occurring luteinizing hormone-releasing hormone (LHRH), and it is used for the treatment of prostate cancer, breast cancer, endometrioza, and abnormal bleeding of the uterus. “The acetate salt of a synthetic decapeptide analog of luteinizing hormone-releasing hormone (LHRH). Continuous, prolonged administration of goserelin in males results in inhibition of pituitary gonadotropin secretion, leading to a significant decline in testosterone production; in females, prolonged administration results in a decrease in estradiol production,” note the National Cancer Institute (NCI) Drug Dictionary.
Both breast and prostate cancer are the second most common types of cancer among women and men respectively, and its growth is often promoted by sex hormones. Therefore, the mechanism of action of goserelin acetate is based on interfering with these hormones to decrease their amount in the body and stop cancer growth. Goserelin acetate is available as an implant that is inserted by a doctor or nurse with a syringe subcutaneously in the area of the stomach. Depending on the patient’s needs and disease, the implant can have 3.6 mg of goserelin inserted every four weeks or 10.8 mg of goserelin to be implanted every 12 weeks. The length of the treatment also depends on the condition being treated and patient’s response to the medication.
Goserelin acetate is used to treat hormone-sensitive cancers of the breast(in pre- and peri-menopausal women) and prostate, and some benign gynaecological disorders (endometrioza, uterine fibroids and endometrial thinning). In addition, goserelin is used in assisted reproduction and in the treatment of precocious puberty. It may also be used in the treatment of male-to-female transgender people and is favoured above other anti-androgens in some countries, such as the UK. It is available as a 1-month depot and a long-acting 3-month depot.
